Redaktion

Guselkumab (TREMFYA®) is a fully human IgG1λ monoclonal antibody developed by Johnson & Johnson to selectively target the p19 subunit of interleukin (IL)-23, a cytokine that plays a key role in various immune-mediated inflammatory diseases. Guselkumab is approved in multiple countries worldwide, including the USA and those of the EU, for the treatment of adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately-to-severely active ulcerative colitis and Crohn's disease. In September 2025, guselkumab received its first pediatric approvals in the USA for the treatment of pediatric patients 6 years of age and older and weighing ≥ 40 kg who either have moderate-to-severe plaque psoriasis and are candidates for systemic therapy or phototherapy, or who have active psoriatic arthritis. Subsequently, guselkumab was approved in December 2025 in the EU for the treatment of moderate-to-severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. Johnson & Johnson is currently undertaking phase III development of guselkumab in pediatric patients with Crohn's disease and ulcerative colitis in various countries. This article summarizes the milestones in the development of guselkumab leading to these first pediatric approvals for plaque psoriasis and psoriatic arthritis.Weiterlesen

Dear Editor, Psoriasis is a chronic, immune-mediated inflammatory dermatosis that affects approximately 3% of the adult population and exerts a substantial impact on health-related quality of life (QoL). The plaque-type variant is the most prevalent clinical form, typically involving the trunk and limbs. The anatomical distribution of psoriatic lesions has been demonstrated to play a critical role in shaping the disease burden, with visible and exposed areas contributing disproportionately to psychosocial distress and functional impairment. [...].Weiterlesen

Psoriasis, long thought to be a chronic immune-mediated dermatological disease, is now being reclassified as a systemic inflammatory disease with substantial metabolic and hepatic complications. Psoriasis affects approximately 2-3% of global population and is associated with up to 50% risk of systemic comorbidities. This mini-review examines the evolving understanding of psoriasis pathogenesis, focusing on the interaction of immunological dysregulation, keratinocyte hyperproliferation, and systemic cytokine release. Tumour necrosis factor- alpha (TNF)-α, IL-17, IL-23, and IL-6 are pro-inflammatory mediators that cause cutaneous plaque formation and reach the systemic circulation, leading to insulin resistance, atherogenesis, and liver inflammation. The review identifies common immuno-metabolic pathways, including TNF-α/NF-κB activation, the IL-23/Th17 axis, and dysregulated PI3K/Akt/mTOR signalling, that contribute to psoriatic illness and associated disorders like metabolic syndrome and metabolic dysfunction-associated steatotic liver disease (MASLD). Epidemiological studies demonstrate that psoriasis patients have a high prevalence of obesity, type 2 diabetes, dyslipidaemia, regardless of established risk factors, supporting the updated classification of NAFLD as MASLD. These findings lend support to the idea that psoriasis is a multi-organ disease caused by chronic low-grade inflammation. Clinically, this requires a transition from skin-centred treatment to thorough systemic examination and customised, multidisciplinary management. Targeted biologic treatments, such as IL-17 and IL-23 inhibitors, offer potential for lowering both systemic inflammation and cutaneous symptoms. This review supports early screening, metabolic monitoring, and lifestyle changes as critical components of long-term psoriatic therapy. Recognising psoriasis as a systemic condition is critical for improving overall patient outcomes, lowering morbidity, and avoiding long-term consequences.Weiterlesen

AimRisankizumab is a high-cost biologic treatment for chronic plaque psoriasis, an immune-mediated inflammatory disease presenting with painful red scaly skin lesions. Inter-individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (PK/PD) model to characterise the relationship between risankizumab exposure and treatment response.MethodsA sequential population PK/PD model was developed using real-world data (UK Biomarkers of Systemic Treatment Outcomes in Psoriasis study) comprising serial PK and Psoriasis Area and Severity Index (PASI) measures. Models were built using R (V4.3.1) and nlmixr2 (V2.1.1.9). One and two-compartment PK models were tested. A maximal effect turnover model was used to describe PASI, with drug effect on lesion development rate (Kin).ResultsThe dataset (82 serum risankizumab concentrations; 101 PASI observations) comprised 50 patients with psoriasis (median weight 79.3 kg; age 47 years). PK data were described by a one-compartment model with first-order absorption/elimination. Absorption rate (Ka) was fixed from the literature (0.229). Estimated clearance was 0.34 L/day, and volume of distribution 12.9 L. Baseline PASI at model initiation, drug potency (EC50) and lesion recovery rate (Kout) were estimated at 23.4, 0.11 mg/L and 0.05 day-1, respectively.ConclusionsPharmacokinetic parameters were similar to risankizumab clinical trials. Kout estimates aligned with other psoriasis turnover models, highlighting the capture of disease dynamics that may be applied across drugs. This model may inform personalised dosing based on individual patient characteristics, drug exposure and response, to optimise treatment outcomes.Weiterlesen

The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon-gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients with a history of malignancy and viral hepatitis.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

BackgroundNarrowband ultraviolet B (NB-UVB) phototherapy is a well-established, safe, and effective treatment for pediatric psoriasis; however, relapse after therapy remains a major challenge. Data regarding prognostic factors influencing remission durability in children are limited.ObjectivesTo evaluate treatment response, relapse patterns, and predictors of relapse-free duration in pediatric psoriasis patients treated with NB-UVB phototherapy, with a particular focus on concomitant topical corticosteroid and calcipotriol use, and clinical features such as nail involvement.MethodsThis multicenter retrospective study included 114 pediatric psoriasis patients treated with NB-UVB across six tertiary dermatology centers in Türkiye. Treatment response was defined as ≥ 75% improvement in the Psoriasis Area and Severity Index (PASI75). Relapse was defined as clinically significant recurrence requiring renewed NB-UVB or systemic therapy within 6 months after treatment completion. Multivariable linear regression identified independent predictors of relapse-free duration.ResultsOf 114 patients (mean age 12.2 ± 3.6 years; 52.6% male), 65.8% achieved PASI75 and 42.1% PASI90. Responders received significantly higher cumulative doses and more sessions than nonresponders (p < 0.001). Relapse occurred in 24.0% of responders within 6 months. In multivariate analysis, concomitant topical corticosteroid use independently predicted longer relapse-free duration (β = 0.578, p = 0.001), whereas nail involvement predicted shorter remission (β = -0.520, p = 0.002). Topical calcipotriol and disease subtype were not significant predictors. NB-UVB was well tolerated, with mild erythema and pruritus as the most frequent adverse events (16.7%).ConclusionNB-UVB phototherapy provides high efficacy and an acceptable safety profile in pediatric psoriasis. Concomitant topical corticosteroid use may prolong remission, while nail involvement identifies patients at higher relapse risk, supporting closer monitoring and individualized follow-up and maintenance strategies.Weiterlesen

BACKGROUND Guttate psoriasis is a form of psoriasis that often occurs following infections and is most commonly triggered by group A Streptococcus. The link between streptococcal pharyngitis and the development of guttate psoriasis is well documented in younger populations; however, this presentation in older adults is less common. Additionally, older adult populations can have multiple comorbidities that could influence the development and clinical course of guttate psoriasis. CASE REPORT We report the case of a 66-year-old woman with multiple comorbidities, including type 2 diabetes mellitus, vitamin D deficiency, colon cancer treated with surgical resection, and endometriosis, who developed guttate psoriasis following a confirmed episode of streptococcal pharyngitis. Initially, the patient's condition was misdiagnosed as tinea versicolor, leading to delays in appropriate treatment. After further dermatologic evaluation and laboratory investigations, the diagnosis of guttate psoriasis was more firmly established, allowing for more tailored treatment decisions. CONCLUSIONS This case highlights guttate psoriasis as a rare post-streptococcal complication in a 66-year-old woman, emphasizing the importance of clinical awareness and accurate diagnosis in older adults with recent upper respiratory infections. Although the exact mechanism of guttate psoriasis development remains unclear, its distinct clinical features allow for its recognition in patients of all ages. Guttate psoriasis also contributes to the understanding of the varied clinical manifestations of streptococcal pharyngitis, particularly in patients with complex medical histories.Weiterlesen

ImportancePatient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits.ObjectiveTo assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis.Design, setting, and participantsThe BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab/bimekizumab-treated patients).InterventionsContinuous bimekizumab-treated patients received bimekizumab, 320 mg, every 4 weeks to week 16, then every 4 weeks or every 8 weeks to 1 year and into the OLE. Secukinumab/bimekizumab-treated patients received secukinumab, 300 mg, every 4 weeks to 1 year, then switched to bimekizumab, 320 mg, every 4 weeks or every 8 weeks. All received bimekizumab every 8 weeks by week 64.Main outcomes and measuresPatient-reported itching/skin pain/scaling (Psoriasis Symptoms and Impacts Measure [P-SIM]) and concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are reported (nonresponder imputation to 1 year; modified nonresponder imputation to 1-3 years).ResultsA total of 373 bimekizumab-treated and 370 secukinumab-treated patients were randomized at baseline; 336 and 318, respectively, entered the OLE. Among bimekizumab-randomized and secukinumab-randomized patients, 127 (34.0%) and 93 (25.1%) reported no itching; 278 (74.5%) and 222 (60.0%) no skin pain; and 172 (46.1%) and 80 (21.6%) no scaling at week 4, respectively; at year 1, rates remained higher in bimekizumab-randomized vs secukinumab-randomized patients (itching: 227 [60.9%] vs 178 [48.1%]; nominal P < .001; skin pain: 293 [78.6%] vs 262 [70.8%]; nominal P = .01; scaling: 263 [70.5%] vs 184 [49.7%]; nominal P < .001). Bimekizumab-randomized patients had greater concurrent achievement rates of PASI = 0 and DLQI 0/1 vs secukinumab-randomized patients (week 4: 43 [11.5%] vs 17 [4.6%]; nominal P < .001; year 1: 230 [61.7%] vs 158 [42.7%]; nominal P < .001). In patients entering the OLE, high P-SIM = 0 rates were maintained to year 3. At OLE entry, concurrent achievement of PASI = 0 and DLQI 0/1 was reported in 69.2% continuous bimekizumab-treated and 48.5% secukinumab/bimekizumab-treated patients. After switching, secukinumab/bimekizumab responses increased, and high rates were maintained to year 3 for both continuous bimekizumab and secukinumab/bimekizumab (62.2% and 63.8%, respectively).Conclusions and relevanceIn this randomized clinical trial and OLE, bimekizumab rapidly and durably improved symptoms/health-related quality of life to 3 years, demonstrating that clinical efficacy translates to quality of life improvements. Secukinumab-randomized patients reported improvements on switching to bimekizumab.Trial registrationClinicalTrials.gov Identifier: NCT03536884.Weiterlesen

ObjectiveTo describe the comorbidity profile in patients with moderate-to-severe psoriasis treated with biologics and their association with clinical phenotype and therapeutic choice.Material and methodsThis was an observational, cross-sectional, single-center study conducted at the Lozano Blesa University Clinical Hospital (Zaragoza, Spain). Consecutive patients with moderate-to-severe psoriasis receiving biologic treatment were included. Data were collected during the Dermatology consultation and reviewed from medical records. The variables analyzed included demographic data, clinical phenotype, previous and current treatments, cardiometabolic comorbidities, neoplasia, infections, and lifestyle habits. Statistical analysis employed means and proportions comparison tests, and logistic regression to explore associations between phenotype, comorbidities, and biologic type.Results350 patients were included (median age 54.1years; 57% men; 84% plaque psoriasis). The most prevalent comorbidities were dyslipidemia (55%), hypertension (42%), and obesity (36%). Among patients with liver elastography, 58% met MASLD criteria. Significant associations were observed between clinical phenotype and comorbidities: plaque psoriasis with hypertension and vitaminD deficiency, erythrodermic psoriasis with alcoholism and neoplasia, pustular psoriasis with dyslipidemia and kidney disease, and guttate psoriasis with a lower prevalence of cardiovascular factors. Guselkumab was the most commonly used biologic (15%).ConclusionsPatients with moderate-to-severe psoriasis have a high burden of comorbidities, with differential profiles according to phenotype. These results reinforce the need for a multidisciplinary approach and the role of primary care in screening and managing comorbidities to improve disease control and overall prognosis.Weiterlesen

BackgroundNail involvement is common in psoriasis, yet objective and non-invasive biomarkers of nail disease activity are limited. The biochemical composition of the nail plate may reflect local pathophysiological changes and could provide measurable indicators of disease severity.ObjectiveTo compare the nail biochemical composition between psoriatic patients with and without nail involvement, and to examine its associations with nail severity.MethodsIn this case-control study, nail clippings from adults with psoriasis were analyzed for trace elements (Cr, Cu, Fe, Mn, Mg, Se, Zn) by ICP-OES and for amino acids by LC-MS/MS. Group comparisons and correlation analyses with the Nail Psoriasis Severity Index (NAPSI) were conducted, and multivariable logistic regression identified independent predictors of nail involvement.ResultsFifty-seven patients were included (30 with nail involvement; 27 without). Compared with patients without nail involvement, those with nail psoriasis showed significantly lower nail levels of several trace elements and amino acids, whereas histidine was higher (all p < 0.05). NAPSI correlated negatively with selenium, zinc, glycine, and proline, and positively with histidine. In multivariable analysis, lower nail selenium and asparagine and higher histidine independently predicted nail involvement.ConclusionPsoriatic nail dystrophy is associated with a distinct biochemical profile in the nail plate. Selected trace elements and amino acids correlate with clinical severity and may represent potential biochemical indicators of nail disease activity. Prospective studies are warranted to validate these findings.Weiterlesen

No abstract supplied.Weiterlesen

IntroductionHuman beta-defensin 2 (hBD-2) is an antimicrobial peptide upregulated by IL-17A and TNF-α, important in skin immunity and inflammation. While hBD-2 is elevated in psoriatic skin, its systemic expression and clinical significance remain unclear, particularly in psoriatic arthritis (PsA).ObjectivesTo compare serum hBD-2 levels among patients with psoriasis vulgaris, PsA, and healthy controls, and to evaluate its correlation with disease severity and inflammatory markers.MethodsThis case-control study included 66 patients with psoriasis, 30 with PsA, and 67 healthy controls. Serum hBD-2, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI). A p value < 0.05 was considered statistically significant.ResultsMedian serum hBD-2 levels were significantly higher in psoriasis and PsA groups compared to controls (p < 0.001), but no significant difference was found between the two patient groups (p: 0.223). In the psoriasis group, hBD-2 showed no significant correlation with PASI (r: 0.218, p: 0.095), CRP (r: 0.158, p: 0.277), or ESR (r: 0.129, p: 0.369). CRP and ESR were significantly higher in the PsA group than in other groups (p < 0.001 and p: 0.002, respectively).ConclusionsAlthough serum hBD-2 is elevated in psoriasis and PsA, it does not correlate with clinical or laboratory disease activity in psoriasis. These findings suggest that hBD-2 may reflect local cutaneous immune activation rather than systemic inflammation.Weiterlesen

BackgroundAsthma (AS) and chronic obstructive pulmonary disease (COPD) are prevalent chronic airway disorders with shared inflammatory pathways. Considering the systemic inflammatory nature of psoriasis, this study utilized the National Health Interview Survey (NHIS) to investigate its potential association with COPD and AS.MethodsData from the 2023 NHIS were analyzed, with participants selected based on specific inclusion criteria. A baseline table was constructed, and multivariate logistic regression models, along with risk stratification analysis, were employed to examine the correlations between psoriasis and COPD and AS. Receiver operating characteristic (ROC) analysis was conducted to assess the predictive value for both conditions.ResultsA total of 27,106 participants were included in the study. Significant differences were observed in the baseline characteristics of psoriasis, age, race, region, gender, education, marital status, employment, income, smoking habits, health status, mental health, disability, heart attack history, BMI, prediabetes, cancer, hypertension, hypercholesterolemia, arthritis, coronary heart disease, stroke, health insurance, anxiety, and depression (P < 0.001). Multivariate logistic regression revealed a strong association between psoriasis and COPD (model 1: OR 2.63, 95% CI: 2.13-3.23, P < 0.001; model 2: OR 2.43, 95% CI: 1.95-2.99, P < 0.001; model 3: OR 1.54, 95% CI: 1.21-1.96, P < 0.001). A similar association was found between psoriasis and AS (model 1: OR 1.68, 95% CI: 1.42-1.97, P < 0.001; model 2: OR 1.74, 95% CI: 1.47-2.05, P < 0.001; model 3: OR 1.32, 95% CI: 1.11-1.56, P < 0.01). The ROC analysis based on model 3 demonstrated substantial predictive power of psoriasis for COPD, with an AUC of 0.881.ConclusionPsoriasis was identified to have a strong association with COPD and AS, which provided valuable insights into understanding the pathogenesis of these diseases.Weiterlesen

# Ärzte lernen: Hautkrankheiten bei dunkler Haut richtig erkennen Medizinstudenten in Hamburg haben ein wichtiges Problem entdeckt. Viele von ihnen konnten Hauterkrankungen bei Menschen mit dunkler Haut anfangs kaum erkennen. Das ist auch für Menschen mit Psoriasis relevant, denn auch hier führt mangelnde Ausbildung zu Fehldiagnosen. Die Studie testete 142 Studierende im vierten Semester. Am Anfang erkannten sie nur 54,8 Prozent der Hautprobleme richtig. Nach einem speziellen Seminar verbesserte sich das dramatisch auf 92,5 Prozent. Besonders schwer hatten die Studierenden anfangs mit Melasma und Wulstnarben. Hier stiegen die Erkennungsraten um über 50 Prozent. Das Seminar vermittelte nicht nur diagnostisches Wissen. Die Studierenden lernten auch grundlegende Unterschiede zwischen heller und dunkler Haut. Sie beschäftigten sich mit Hauttyp-Klassifizierungen. **Warum das wichtig ist:** Hauterkrankungen sehen bei dunklerer Haut oft anders aus als in den meisten Lehrbüchern gezeigt. Das führt dazu, dass Menschen mit Psoriasis oder anderen Hautproblemen länger auf die richtige Diagnose warten. Die Studie zeigt, dass gezielte Ausbildung das ändern kann. Wenn solche Seminare Standard werden, bekommen alle Patienten bessere medizinische Versorgung. Originaltitel: Testing undergraduate medical students' ability to correctly identify skin conditions in skin of color-A pre-post-study at a medical school in Germany. Link zur Quelle

# Biosimilar Adalimumab bei Schuppenflechte Ich kann dir leider keine plain language summary des spezifischen ADACCESS-Artikels aus der Zeitschrift Immunotherapy geben, da dieser nicht in meinen Suchergebnissen vorhanden ist. Allerdings zeigen die verfügbaren Studien zu **GP2017** (einem Biosimilar von Adalimumab) und dem Original-Adalimumab bei Schuppenflechte folgendes:[1][5] **Das Wichtigste:** Das Biologikum GP2017 wirkt genauso gut wie das Original-Adalimumab. Bei etwa zwei Dritteln der Patienten besserte sich die Schuppenflechte nach 16 Wochen um mindestens 75 Prozent.[1][5] **Das bedeutet für dich:** Es gab keinen Unterschied in der Wirksamkeit zwischen beiden Medikamenten. Auch die Sicherheit war vergleichbar. Sogar wenn Patienten mehrmals zwischen GP2017 und dem Original wechselten, funktionierte die Behandlung weiterhin gut.[1][5] **Zusätzliche Info:** Eine andere Untersuchung zeigte, dass die Psoriasis-Werte stabil blieben, wenn Patienten zu GP2017 oder einem anderen Biosimilar wechselten.[4] Für den genauen ADACCESS-Artikel empfehle ich dir, die Publikation direkt über deinen Bibliothekszugang zu suchen. Originaltitel: Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial Link zur Quelle

Originaltitel: Vision transformer-based diagnosis of psoriasis and eczema in whole-slide histology. Link zur Quelle

Originaltitel: Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial. Link zur Quelle

# Neue Biologika gegen Psoriasis: Das Infektionsrisiko ist kleiner als befürchtet Französische Forscher haben eine große Studie durchgeführt. Sie wollten wissen, wie sicher verschiedene Biologika wirklich sind. Dafür schauten sie sich knapp 40.000 Menschen mit Psoriasis an. Diese Menschen bekamen zwischen 2013 und 2022 Biologika. Das Ergebnis ist beruhigend: Die Infektionen, die so schwer sind, dass man ins Krankenhaus muss, kommen selten vor. Sie traten nur bei etwa 27 von 1.000 Menschen pro Jahr auf. Aber es gibt Unterschiede zwischen den Medikamenten. Einige wirken sicherer als andere. Das Mittel Ustekinumab und die sogenannten IL-23-Hemmer hatten das niedrigste Infektionsrisiko. Auch Secukinumab und Risankizumab schnitten gut ab. Sie führten zu weniger Infektionen als das häufig verschriebene Adalimumab. Die Studie zeigt also: Menschen mit Psoriasis brauchen vor Biologika keine übertriebene Angst zu haben. Besonders wenn der Arzt die richtigen Biologika aussucht. Originaltitel: Infection risk among psoriasis biologic-new users: A cohort study on the French National Health Data System Link zur Quelle

Originaltitel: Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. Link zur Quelle

Originaltitel: Efficacy of Flaxseed Oil in Treating Mild to Moderate Psoriasis Vulgaris Compared with Topical Betamethasone: A Randomized, Double-Blind, Clinical Trial Link zur Quelle

# Neue Hoffnung aus der Forschung: Mikronadelflaster gegen Schuppenflechte Forscher arbeiten an einem innovativen Flaster, das zwei Wirkstoffe direkt in die Haut bringt.[4] Das Flaster nutzt winzige Nadeln, um Methotrexat und Dexamethason zu transportieren. Warum ist das besser als Tabletten? Der Wirkstoff gelangt direkt zur erkrankten Haut.[1] So vermeidet man die Magensäure und belastet Leber sowie Nieren nicht.[3] Das ist wichtig, weil Methotrexat bei Tabletten starke Nebenwirkungen haben kann. Das Flaster hat zwei Schichten.[4] Das ermöglicht eine zeitlich abgestimmte Wirkstofffreisetzung. Die Forscher berichten, dass die Mikronadelreihe deutlich mehr Wirkstoff in erkrankte Haut bringt als in gesunde.[1] Das Methotrexat hemmt die überschießende Zellteilung bei Schuppenflechte. Das Dexamethason bekämpft zusätzlich die Entzündung. Für Psoriasis-Patienten könnte das eine echte Alternative werden. Man müsste nicht mehr wöchentlich Tabletten nehmen. Ein Flaster wäre praktikabler und hätte weniger Nebenwirkungen. Die Forschung zeigt: Topische Behandlungen könnten die Zukunft sein. Originaltitel: A bilayered microneedle patch loaded with methotrexate and dexamethasone for transdermal treatment of psoriasis - Scientific Reports Link zur Quelle

Originaltitel: Development of a shared decision-making tool for systemic treatment in psoriasis Link zur Quelle

**Bluttest statt Raterei: So erkennen Ärzte Handekzem und Schuppenflechte sicherer** Viele Menschen mit Handerkrankungen kennen das Problem: Ärzte sind sich unsicher, ob es sich um Handekzem oder Schuppenflechte handelt.[1] Beide Krankheiten sehen sich sehr ähnlich. Das macht die richtige Behandlung schwierig. Jetzt gibt es endlich Hoffnung. Forscher haben eine Methode entwickelt, die klare Antworten liefert.[1] Sie analysieren zwei Gene in der Haut. So können sie genau bestimmen, welche Krankheit vorliegt. Bei einer großen Studie war dies in über 95 Prozent der zweifelhaften Fälle erfolgreich.[1] Das Ergebnis: Patienten bekamen die richtige Behandlung. Nach zwei Jahren waren die Symptome deutlich milder.[1] Auch das Kortison wurde weniger genutzt, stattdessen kamen gezielte Systemtherapien zum Einsatz.[1] Das Beste: Die Lebensqualität verbesserte sich massiv.[1] Die Belastung durch die Erkrankung halbierte sich fast. Die Patienten litten weniger unter Juckreiz und Einschränkungen im Alltag. Die Methode ist besonders wichtig für Menschen mit Berufsekzemen. Sie könnten schneller wieder arbeiten und ihre Haut gesünder werden lassen.[1] Originaltitel: Molecular Diagnostics in Hand Dermatoses: Clinical Findings and Health-Related Quality of Life in a 3-Year Follow-Up Cohort Study - Dermatology and Therapy Link zur Quelle